J&J, Merck and Pfizer spent tax savings on investor payouts, not R&D: Oxfam

The Tax Cuts and Jobs Act, a signature piece of legislation from President Donald Trump in 2017, has been a windfall for big business. It was supposed to be a job-creation and investment engine, too. But top drugmakers channeled most of their savings to investors, not R&D or price cuts.